Caribou Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Caribou Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.9 times its market value (net cash). Higher than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-17.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 56% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 19%
Sales fell 19% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-19% / -53%In 3 years sales changed by -19% while total assets changed by -53%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-92.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 82% of Healthcare companies in United States.
Cash Cushion Ratio
1.9× cashCash, after subtracting all debt, is 1.9 times its market value (net cash).
Higher than 95% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Caribou Biosciences, Inc. made a loss over the last year. Caribou Biosciences, Inc. owes $0.31 for every $1 it owns. Caribou Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCaribou Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.61The share price is 0.61 times Caribou Biosciences, Inc.'s book value per share, lower than 88% of Healthcare companies in United States.
Market cap
$60 MThe total market value of all of Caribou Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than 72% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$98 MWhat Caribou Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.92Net worth divided by the number of shares. The share price of $0.56 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-78.3%Caribou Biosciences, Inc. lost 78.3% of its shareholders' money over the last year, lower than 64% of Healthcare companies in United States.
Owes vs Owns
0.31×Caribou Biosciences, Inc. owes $0.31 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Dividend yield
NoneCaribou Biosciences, Inc. does not currently pay a dividend.
Revenue growth
+12%Revenue rose 12% in the year to Dec 2025, and shrank 7% a year on average over 3 years.
Profit growth
LossCaribou Biosciences, Inc. made a loss in each of the last two years.
Profit margin
-1327.4%Caribou Biosciences, Inc. lost $1327 for every $100 of revenue.
Cash vs debt
Net cashCaribou Biosciences, Inc. held $112 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Caribou Biosciences, Inc.: $60 M ÷ $98 M (30 Jun 2026) = 0.6.
What is Caribou Biosciences, Inc.'s return on equity?
Caribou Biosciences, Inc. lost 78.3% of its shareholders' money over the last year, lower than 64% of Healthcare companies in United States.
How much does Caribou Biosciences, Inc. owe compared with what it owns?
Caribou Biosciences, Inc. owes $0.31 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Does Caribou Biosciences, Inc. pay a dividend?
No. Caribou Biosciences, Inc. does not currently pay a dividend.
Is Caribou Biosciences, Inc.'s revenue growing?
Revenue rose 12% in the year to Dec 2025, and shrank 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.